Systems and methods for delivery of a therapeutic agent

Patent metadata

Field	Value
Publication number	US-11679077-B2
Application number	US-202117151938-A
Country	US
Kind code	B2
Filing date	Jan 19, 2021
Priority date	Jul 22, 2005
Publication date	Jun 20, 2023
Grant date	Jun 20, 2023

Abstract

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

First claim

What is claimed is:

1. An apparatus for treating rhinitis in a nasal cavity, the apparatus comprising:
an elongate body, comprising:
a proximal portion; and
a distal portion configured for positioning in the nasal cavity;

multiple radiofrequency electrodes coupled with the distal portion of the elongate body; and
a radiofrequency generator coupled with the proximal portion of the elongate body for supplying radiofrequency energy to the multiple radiofrequency electrodes to treat a target tissue in the nasal cavity and thus treat rhinitis.

2. The apparatus of claim 1 , wherein the multiple radiofrequency electrodes comprise at least two bipolar radiofrequency electrodes.

3. The apparatus of claim 2 , further comprising at least one sensing electrode.

4. The apparatus of claim 2 , wherein the at least two bipolar radiofrequency electrodes comprise multiple pairs of bipolar radiofrequency electrodes.

5. The apparatus of claim 1 , wherein the target tissue comprises nerve tissue.

6. The apparatus of claim 1 , wherein at least one of the multiple radiofrequency electrodes is movable relative to the distal portion of the elongate body.

7. The apparatus of claim 1 , wherein the multiple radiofrequency electrodes are configured to deliver energy laterally relative to the distal portion of the elongate body.

8. The apparatus of claim 1 , wherein at least one of the multiple radiofrequency electrodes is configured to extend laterally from the distal portion of the elongate body.

9. The apparatus of claim 7 , wherein the at least one of the multiple radiofrequency electrodes is configured to penetrate nasal mucosa lining the nasal cavity.

10. The apparatus of claim 1 , further comprising a thermocouple coupled with the distal portion of the elongate body for sensing temperature of a nasal tissue in the nasal cavity.

11. The apparatus of claim 1 , further comprising a monitoring system coupled with the distal portion of the elongate body for monitoring a degree of treatment of the target tissue.

12. The apparatus of claim 1 , further comprising an agent delivery element coupled with the distal portion of the elongate body for delivering a therapeutic agent to the target tissue.

13. The apparatus of claim 12 , wherein the agent delivery element comprises at least one needle.

14. The apparatus of claim 13 , further comprising a source of the therapeutic agent coupled with the proximal portion of the elongate body.

15. The apparatus of claim 14 , wherein the therapeutic agent comprises a neurotoxin.

Assignees

• Foundry Llc

Inventors

• Deem Mark E
• Gifford Hanson

Classifications

• A61N2007/003

  Destruction of nerve tissue · CPC title

• C12Y304/24069

  Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin · CPC title

• A61N1/303

  Constructional details (electrodes for external use A61N1/0428) · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K38/164

  from bacteria · CPC title